55th ICAAC, San Diego, September 2015
Reference No.
Document title
Authors
A-471
Pharmacodynamics of aztreonam against E.coli studied in an in vitro model of infection
C Ramsey, KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, A P MacGowanA-472
Pharmacodynamics of Ceftaroline Against Proteus mirabilis
Pre-clinical Clinical Correlates
A. Noel, K. Bowker, S. Tomaselli, M. Attwood, A. MacGowanA-497
Pharmacodynamics of minocycline plus rifampicin against S.aureus studied in an in vitro model of infection
KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, AP MacGowanA-506
Comparison of the Antibacterial Effects of Two Dosing Regimens of Ceftolozane (TOL) in Combination with Tazobactam (TAZ) against Enterobacteriaceae
KE Bowker, AR Noel, MLG Attwood, ST Tomaselli, AP MacGowan
54th ICAAC, Washington DC, September 2014
Reference No.
Document title
Authors
A-040
Pharmacodynamics of Minocycline against Acinteobacter baumannii studied in a pharmacokinetic Model of Infection
KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowanA-042
Pharmacodynamics of Amikacin against Aerobic Gram-negative Rods studied in an in vitro Model of Infection
AR Noel, KE Bowker, SG Tomaselli, D Nicholls, AP MacGowanA-1347
Pharmacokinetic driver of avibactam effect against β-lactamase-producing Enterobacteriaceae established in an in vitro pharmacokinetic model of infection-1347
KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowan
A-1182Pharmacodynamics of ceftolozane/tazobactam against P.aeruginosa (PSA) Studied in an In Vitro Model of Infection.KE Bowker, AR Noel, SG Tomaselli, D Nicholls, AP MacGowan
A-1347a
Pharmacokinetic driver of avibactam effect against β-lactamase-producing Enterobacteriaceae
established in an in vitro pharmacokinetic model of infection
AP MacGowan, AR Noel, SG Tomaselli, D Nicholls, KE Bowker
53rd ICAAC, Denver, September 2013
Reference No.
Document title
Authors
A-1015
Pharmacodynamics of minocycline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection
AR Noel, KE Bowker, SG Tomaselli, , AP MacGowan, WW HopeA-1029
Pharmacodynamics of ceftolozane/tazobactam against Gram-negative bacilli
KE Bowker, AR Noel, SG Tomaselli, HG Elliott, AP MacGowanA-022
Pharmacodynamics of Glycopeptides in Combination with Rifampicin for Methicillin Resistant Staphylococcus aureus (MRSA) Infections
J . Sharp , J. Livermore, L. Gregson, J. Goodwin, A.P. MacGowan, W.W. HopeA-464
fT>MIC Targets May Vary for Cephalosporins Within the Enterobacteriaceae Group
Karen E Bowker, Alan R Noel,1 Jane Ambler, Alasdair P MacGowanA-009
Pharmacodynamics of single dose Oritavancin against Staphylococcus aureus
KE Bowker, AR Noel, SG Tomaselli, HG Elliott, AP MacGowan
52nd ICAAC, San Francisco, September 2012
Reference No.
Document title
Authors
A-024
Pharmacodynamics of doripenem against Pseudomonas aeruginosa and Acinetobacter spp
AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-628
Assessment of the Antistaphylococcal Effect of Ceftaroline in
Long Duration Human Dose Simulations: Impact of MIC
AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-629
Pharmacodynamics of Ceftaroline against Enterobacteriaceae
AR Noel, KE Bowker, SG Tomaselli, AP MacGowanA-631
The pharmacodynamics of Avibactam (NXL104) in Cobination with Either Ceftaroline or Ceftazidime against Blactamase producing Enterobacteriaceae
AR Noel, SG Tomaselli, DL Nicholls, KE Bowker, G Williams, AP MacGowanA-642
Pharmacodynamics of piperacillin-tazobactam (P/T) against Pseudomonas aeruginosa: antibacterial effect and risk of emergence of resistance
AR Noel, KE Bowker, AP MacGowanD-763
Colistin MIC Testing: The Effect of Different Types of Microtitre Trays and Surfactant Tween 80 in Broth Microdilution Method
E Sweeney, S Nelson, A Lovering, K BowkerE-793
Bactericidal Activity of Multiple Combinations of Fosfomycin and Colistin against NDM-1 producing Enterobacteriaceae
KE Bowker, AP MacGowan
51st ICAAC, Chicago, Sep 2011
Reference No.
Document title
Authors
A2-556
Pharmacodynamics of Avibactam Plus Either Ceftaroline or Ceftazidime Against an AmpC-Producing Enterobacter spp
AR Noel, KE Bowker, AP MacGowan, G WilliamsA2-557
Pharmacodynamics of Ceftaroline Plus Avibactam Against Enterobacteriaceae Studied in an In Vitro Pharmacokinetic Model of Infection
K.E. Bowker, A.R. Noel, S.G. Tomaselli, A.P. MacGowan, G. WilliamsA1-1159/6
Pharmacokinetics and Safety of Daptomycin in Young Infants
P Brian Smith, Michael Cohen-Wolkowiez, Kevin Watt, Daniel K Benjamin Jr.E-721
Bactericidal Activity of Multiple Combinations of Tigecycline and Colistin against NDM-1 producing Enterobacteriaceae
M. Albur, A. Noel, K. Bowker, A. MacGowanA2-555
Pharmacodynamics of Ceftaroline against Staphylococcus aureus
Studied in an In Vitro Pharmacokinetic Infection Model
Alan R Noel, Karen E Bowker, Sharon G Tomaselli, Alasdair P MacGowanC2-093
Community-based Nasal Screening Poorly Predicts pvl Carriage and Antimicrobial Resistance in Communityacquired
S.aureus Infection
A. Lovering, J. Sunderland, E. Woodward, J Steer, A. Hidalgo-ArroyoF1-314
A monobactam plus double b-lactamase inhibitor combination (BAL30376) designed to overcome multiple resistance in Gram-negative bacilli: proof of concept in an in vitro pharmacokinetic model
KE Bowker, AR Noel, AP MacGowan
50th ICAAC, Boston, Sep 2010
Reference No.
Document title
Authors
A1-673
Changes in Streptococcus pneumoniae population profiles after
exposure to fluoroquinolones in prolonged dosing simulations
KE.Bowker, AR.Noel, HC.Elliott, SG.Tomaselli and AP.MacGowanA1-1383
Pharmacodynamics of Razupenem (PTZ601) against Enterobacteriaceae
KE. Bowker, AR. Noel, SG. Tomaselli, HC. Elliott, AP. MacGowanA1-1367
The magnitude of the pharmacodynamic index required for a 24h bacteriostatic effect for S.aureus is associated with increased risk of resistance
KE. Bowker, AR. Noel, HC. Elliott, SG. Tomaselli and AP. MacGowanA1-1377
Comparison of the Antibacterial Effects of Two Dosing Regimens of Ceftaroline in Combination With NXL104 Against Enterobacteriaceae
K. Bowker, A. Noel, H. Elliott, S. Tomaselli, A. MacGowanA1-1382
Pharmacokinetic-Pharmacodynamic Basis for CLSI Carbapenem Susceptibility Breakpoint Changes
Sujata M. Bhavnani, Michael N. Dudley, Cornelia Landersdorfer, George L. Drusano, William A. Craig, Ronald N. Jones, Paul G. Ambrose
Bcare (ARL) Contact Details
Antimicrobial Reference Laboratory
Level 2, Phase 1, Pathology Sciences Building
Southmead Hospital
Westbury-on-Trym
Bristol
BS10 5NB
Telephone: 0117 4146269 or 0117 4146220
Fax: 0117 4146282
Email: arlenquiries@nbt.nhs.uk